AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PDS Biotechnology Soars 17.83% on Positive Cancer Trial Data
Generated by AI AgentAinvest Pre-Market Radar
Friday, May 23, 2025 4:11 am ET1min read
On May 23, 2025, PDS Biotechnology's stock surged by 17.83% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent developments.
PDS Biotechnology has announced positive extended follow-up data for the VERSATILE-002 trial, which evaluated Versamune® HPV in head and neck cancer patients. The trial demonstrated a median overall survival of 39.3 months for patients with a Combined Positive Score (CPS) of 20, highlighting the potential efficacy of the treatment.
Additionally, the company will present several abstracts during the Head and Neck Cancer Poster Session, scheduled from May 30 to June 3, 2025. These presentations will include updates on the ongoing VERSATILE-003 trial and other studies involving Versamune® HPV, further underscoring the company's commitment to advancing cancer treatments.
PDS Biotechnology's encouraging survival data for Versamune® HPV combined with pembrolizumab in head and neck cancer trials has also contributed to the positive market sentiment. This data suggests that the combination therapy may offer promising outcomes for patients, potentially driving further investment in the company's research and development efforts.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Galiano Gold TSE:GAU shares surge 5.35% on renewed investor confidence extending upward trend.
Dec.22 2025
Integra Resources surges 8.62% amid strategic operational updates and market dynamics.
Dec.22 2025
Lithium Argentina shares surged 9.49% driven by robust demand and stable supply chains in lithium sector.
Dec.22 2025
Oracle shares surge 6.63% on renewed investor confidence in strategic AI positioning
Dec.22 2025
Broadcom shares surge 3.18% on analyst upgrades and AI infrastructure momentum
Dec.22 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet